Brief: FDA Approves Guardant360 CDX As Companion Diagnostic For Eli Lilly
29/09/2025 13:48
Sept 29 (Reuters) - Guardant Health Inc GH.O: FDA APPROVES GUARDANT360® CDX AS COMPANION DIAGNOSTIC FOR ELI LILLY AND COMPANY’S INLURIYO™ (IMLUNESTRANT) FOR TREATMENT OF ESR1-MUTATED ADVANCED BREAST CANCER Source text: ID:nBw8PDYNPa Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment